Ocular Hypertension Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitec

DelveInsight's, "Ocular Hypertension - Pipeline Insight, 2025" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight highlights that more than 70 key companies are actively working on the development of over 75 treatment therapies for Ocular Hypertension.

Ocular Hypertension Overview:

Ocular hypertension occurs when intraocular pressure (IOP) exceeds the normal range, surpassing 21 mm Hg. While this condition becomes more common with age, it can also result from other factors or disorders. Elevated eye pressure is a significant risk factor for glaucoma, making individuals with ocular hypertension more susceptible to developing the disease. However, the two conditions are distinct-ocular hypertension refers to high intraocular pressure without optic nerve damage, whereas glaucoma involves optic nerve damage, which may occur even when IOP is within the normal range. If left untreated, glaucoma can lead to peripheral vision loss and, in advanced stages, central vision impairment.

In the United States, the prevalence of ocular hypertension among non-Hispanic Whites aged 40 and older is approximately 4.5%, rising to 7.7% in individuals aged 75 to 79. Among Latinos, prevalence rates are similar across different age groups. Since ocular hypertension typically presents without noticeable symptoms, a significant number of affected individuals remain undiagnosed. According to the Los Angeles Latino Eye Study, 75% of Latinos with eye pressure above 21 mm Hg were previously unaware of their condition.

Ocular hypertension is primarily caused by dysfunction in the eye's drainage system, which regulates the flow of aqueous humor-a fluid responsible for nourishing ocular structures. When the drainage system malfunctions, the balance between fluid production and outflow is disrupted, leading to a gradual or sometimes sudden increase in intraocular pressure.

Request for a detailed insights report on Ocular Hypertension pipeline insights [https://www.delveinsight.com/report-store/ocular-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

"Ocular Hypertension Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Ocular Hypertension Therapeutics Market.

Key Takeaways from the Ocular Hypertension Pipeline Report

*
DelveInsight's Ocular Hypertension pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ocular Hypertension treatment.

*
In December 2024, Nicox announced that its Denali Phase III trial, assessing the efficacy and safety of NCX470 in patients with open-angle glaucoma or ocular hypertension, has reached full enrollment in China, and participant screening has concluded.

*
In November 2024, MediPrint Ophthalmics shared the results of its Phase IIb clinical trial for LL-BMT1. The study utilized an innovative 3D-printed, drug-eluting contact lens designed for the sustained release of bimatoprost and hyaluronic acid, successfully meeting all Phase IIb trial endpoints.

*
In October 2023, SpyGlass Pharma initiated a Phase I/II clinical trial evaluating its intraocular drug delivery platform for patients with glaucoma and visually significant cataracts. The SpyGlass system is designed for implantation during routine cataract surgery, enabling long-term delivery of bimatoprost to reduce intraocular pressure (IOP) in individuals with open-angle glaucoma or ocular hypertension.

*
In April 2024, Qlaris Bio completed a $24 million Series B funding round to advance QLS111, a first-in-class drug candidate aimed at lowering IOP for glaucoma treatment. The company also announced the initiation and dosing of two separate U.S. Phase II randomized clinical trials investigating QLS111 in patients with ocular hypertension and glaucoma.

*
In March 2024, Nicox published findings from its Mont Blanc pivotal Phase III trial in the American Journal of Ophthalmology, comparing NCX470 to latanoprost for IOP reduction in patients with open-angle glaucoma or ocular hypertension.

*
Key Ocular Hypertension companies such as Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, LLC, JeniVision, Inc., AbbVie, Santen, VivaVision Biotech, ONL Therapeutics, Skye Bioscience, MediPrint Ophthalmics, Sun Pharma Advanced Research Company, Ripple Therapeutics, Peregrine Ophthalmic, Laboratorios Sophia, Whitecap Biosciences, pH Pharma, Chong Kun Dang, Laboratoires Thea, and others are evaluating new drugs for Ocular Hypertension to improve the treatment landscape.

*
Promising Ocular Hypertension pipeline therapies in various stages of development include NCX-470, QLS-101, TO-O-1001, and others.

Ocular Hypertension Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Ocular Hypertension Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ocular Hypertension treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Ocular Hypertension market.

Download our free sample page report on Ocular Hypertension pipeline insights [https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Ocular Hypertension Emerging Drugs

*
NCX-470: Nicox

*
QLS-101: Qlaris Bio

*
TO-O-1001: TheratOcular Biotek Co., Ltd.

Ocular Hypertension Companies

Over 70 key companies are actively involved in developing treatments for ocular hypertension. Among these, Nicox has the most advanced drug candidates, which are currently in Phase III clinical trials.

DelveInsight's report covers around 75+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Ocular Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Ocular Hypertension Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Ocular Hypertension Therapies and Key Companies: Ocular Hypertension Clinical Trials and advancements [https://www.delveinsight.com/report-store/ocular-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Ocular Hypertension Pipeline Therapeutic Assessment

- Ocular Hypertension Assessment by Product Type

- Ocular Hypertension By Stage

- Ocular Hypertension Assessment by Route of Administration

- Ocular Hypertension Assessment by Molecule Type

Download Ocular Hypertension Sample report to know in detail about the Ocular Hypertension treatment market @ Ocular Hypertension Therapeutic Assessment [https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Ocular Hypertension Current Treatment Patterns

4. Ocular Hypertension - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Ocular Hypertension Late-Stage Products (Phase-III)

7. Ocular Hypertension Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Ocular Hypertension Discontinued Products

13. Ocular Hypertension Product Profiles

14. Ocular Hypertension Key Companies

15. Ocular Hypertension Key Products

16. Dormant and Discontinued Products

17. Ocular Hypertension Unmet Needs

18. Ocular Hypertension Future Perspectives

19. Ocular Hypertension Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Ocular Hypertension Pipeline Reports Offerings [https://www.delveinsight.com/report-store/ocular-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ocular-hypertension-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-nicox-qlaris-bio-theratocular-biotek-co-ltd-ocular-therapeutix-whitec]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.